Truist raises Teladoc stock price target to $9 on EBITDA outlook
Truist Securities has increased its price target for Teladoc Health shares to $9.00 from $8.00, maintaining a Buy rating, following the company's strong third-quarter 2026 results and an improved EBITDA outlook. The firm adjusted its revenue and EBITDA estimates, noting a valuation implying a strong free cash flow yield. Other firms like Piper Sandler, UBS, and Stifel also raised their price targets for Teladoc, acknowledging positive margin performance and growth in its BetterHelp segment.
Teladoc Health Expands Comprehensive Weight Care Program with Employer Contribution Option for GLP-1 Medications
Teladoc Health has expanded its Comprehensive Weight Care program to include an employer contribution option for FDA-approved GLP-1 medications, such as those from Eli Lilly and Company and Novo. This new offering aims to provide employers with greater flexibility in covering GLP-1 costs for their workforce while ensuring predictable spending. The program also integrates comprehensive clinical care, nutrition, and lifestyle support to achieve sustained health outcomes for employees and their families.
Teladoc Launches Employer Contribution Option for GLP-1s
Teladoc Health has introduced a new offering that allows employers to contribute to the cost of GLP-1 medications for their employees, separate from traditional pharmacy benefits. This initiative aims to address the challenges employers face in covering GLP-1s for weight loss, providing a flexible contribution model with transparency and optional participant engagement requirements. The program also integrates guidance from obesity medicine clinicians, dietitians, and health coaches, emphasizing comprehensive support beyond just medication.
GLP-1 medication coverage expands with Teladoc Health weight care program update
Teladoc Health has enhanced its comprehensive weight care program by introducing an employer contribution option for GLP-1 medications, aiming to make weight loss treatments more accessible to employees. This initiative is part of Teladoc Health's broader strategy to expand its digital health services, following its Q3 2026 earnings report and a partnership with Walmart for virtual urgent care, dermatology, and nutrition support.
Teladoc Health Expands Comprehensive Weight Care With Employer-Funded GLP-1 Access Option
Teladoc Health has expanded its Comprehensive Weight Care program to allow employers to offer FDA-approved GLP-1 medications from Eli Lilly and Novo, alongside comprehensive clinical and lifestyle support, while ensuring predictable medication spending. This initiative addresses the high demand for GLP-1s and the current lack of employer coverage for weight loss, providing flexible options for organizations. The new employer contribution model will be available starting January 1, 2027, and is supported by new research demonstrating the effectiveness of sustained lifestyle support in achieving significant long-term weight loss.
Teladoc Health Expands Comprehensive Weight Care Program
Teladoc Health has expanded its Comprehensive Weight Care program, offering employers a new option to contribute to the cost of FDA-approved GLP-1 medications from Eli Lilly and Novo. This initiative aims to provide predictable spending for employers and greater access to comprehensive weight care, including clinical support, nutrition, and lifestyle resources, for employees. New research from Teladoc Health also highlights that sustained lifestyle support leads to increased clinically meaningful weight loss over two years.
A medical research institute reports over 5% ownership of Teladoc Health (TDOC).
American Century Investment Management, Inc., its parent American Century Companies, Inc., and Stowers Institute for Medical Research have jointly reported a beneficial ownership of 9,511,923 common shares of Teladoc Health, Inc. (TDOC), representing 5.2% of the class. This disclosure, filed via Schedule 13G, indicates that each entity holds sole voting and dispositive power over these shares as of September 30, 2026. The filing emphasizes that these are shared holdings, not separate individual positions to be aggregated.
Teladoc Health (TDOC) Stock Could Be Below Fair Value On A 92% Five Year Slump
Teladoc Health (TDOC) has experienced a significant 92.5% share price decline over the past five years, prompting questions about whether its current valuation aligns with its expected future cash flows. A Discounted Cash Flow (DCF) analysis suggests the stock may be undervalued compared to its intrinsic value. However, investor sentiment is split, with some bullish narratives pointing to strong potential if the business model effectively converts virtual care usage into recurring revenue, while bearish arguments highlight challenges like rising compliance burdens and reimbursement pressure.
A $400 Billion Healthcare Opportunity: Telehealth Companies Positioned to Capitalize on a Massive Industry Shift
The telehealth market is experiencing significant growth, driven by patient demand for easier access to care, hospital efficiency needs, and technological advancements like AI and remote monitoring. Valued at $77.4 billion in 2025 and projected to reach $187.5 billion by 2033, the industry is seeing companies like Rocket Doctor AI, Teladoc Health, Amwell, Hims & Hers Health, and Doximity developing innovative platforms to meet this expanding demand. Key drivers include AI for diagnostics, remote patient monitoring, increased demand for virtual care, and pressure to control healthcare costs.
Empire Life folds men’s health care into group benefits at no added cost
Empire Life has integrated a men's health program into its Extended Health Benefits in Canada at no additional cost for eligible plan members and dependants. Delivered through Teladoc Health Canada’s Expert Medical Opinion Service, the program offers virtual access to clinical guidance, recommendations, and health coaching across areas like hormonal health, mental well-being, and preventive care. This initiative aims to address the significant delays men often experience in seeking medical care and managing stress, leveraging virtual support to provide early answers and tailored action plans.
At $9.20 a share, Teladoc Health (TDOC) executive sells 29,432 shares under a trading plan.
Carlos Nueno, President, International for Teladoc Health, Inc. (TDOC), sold 29,432 common shares at $9.20 per share on November 6, 2026. This transaction was executed under a Rule 10b5-1 trading plan adopted on August 4, 2026. Following the sale, Nueno directly holds 35,312 shares of the company.
TD Cowen maintains Teladoc Health at Hold, raises price target to $8 from $6
TD Cowen has maintained its "Hold" rating on Teladoc Health and increased its price target from $6 to $8, representing a 33.3% rise. The new price target suggests an 8.8% downside from Teladoc's closing price on November 6. This update follows several other analyst actions on Teladoc Health over the past 30 days, with price targets ranging from $8 to $10.
QC Healthcare Names Telemedicine Pioneer Michael Gorton, Founder of Teladoc, as Strategic Business Advisor
QC Healthcare has announced that Michael Gorton, the founder of Teladoc, will join the company as a Strategic Business Advisor. Gorton, a telemedicine pioneer and serial entrepreneur, will guide QC Healthcare in scaling its physician-led telehealth platforms and strengthening relationships with payers, health networks, and self-insured employers. The company is developing platforms like My Pediatric Doctor, My Adult Doctor, My VA Doctor, and My Oncology Doctor, offering a single family membership plan for $50 a month with affordable per-visit costs.
Form 144 Teladoc Health For: 7 November By Investing.com
This article reports on the filing of Form 144 by Teladoc Health on November 7, 2026. Form 144 is a notice of the intent to sell restricted securities, indicating potential insider activity or significant changes in holdings for the company. The report notes Teladoc Health's stock (TDOC) was down 6.80% at the time of publication.
Form 144 Teladoc Health For: 7 November By Investing.com
This article reports on a Form 144 filing for Teladoc Health (TDOC) on November 7, 2026, indicating a -6.80% change in the stock price. Form 144 is filed with the SEC when an insider intends to sell restricted or controlled securities. The article provides the title and a Reuters image without additional details regarding the filing's specifics.
Teladoc Health, Inc. (TDOC) Seasonal returns chart
The article provides a brief overview of Teladoc Health, Inc. (TDOC), showing its real-time price and daily change. It highlights that seasonality data is currently unavailable for TDOC. The page includes standard market information and navigation options.
Why Teladoc Health (TDOC) Is Down 6.8% And What's Next
Teladoc Health recently reported its third-quarter 2026 results, showing narrowed net losses despite softer year-to-date sales. The company has provided a new full-year outlook for revenue and net loss per share, emphasizing efficiency and the adoption of Teladoc One and Integrated Care. This guidance suggests a focus on cost control and utilization to drive future results, while also highlighting potential pressure on BetterHelp margins.
Wells Fargo maintains Teladoc Health at Equal-Weight, raises price target to $8 from $6
Wells Fargo has reaffirmed its "Equal-Weight" rating for Teladoc Health (TDOC) while increasing its price target from $6 to $8. This new target suggests a 17.5% downside from the stock's closing price of $9.70 on November 4th. Other analysts have recently issued price targets ranging from $6.50 to $10, with ratings varying from Hold to Outperform.
Teladoc Health (TDOC) Shares Just Climbed, So What Is Driving Attention Now?
Teladoc Health (TDOC) recently saw a significant surge in its share price following the release of its Q3 2026 results and new guidance for Q4 and the full year. Despite a long-term decline, the stock has shown strong momentum with substantial short-term returns. The market is split, with some investors seeing the company as undervalued at $15.00 against a last close of $9.70, citing its cash-generative nature and an expanding insurance-reimbursed mental health model.
Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08
Teladoc Health, Inc. announced that it granted inducement awards to three new employees on November 1, 2026, following the acquisition of Teledigm Health, LLC. These awards consist of restricted stock units covering 40,768 shares of Teladoc Health's common stock, vesting over three years based on continued service. The grants were approved by the Compensation Committee of the Board of Directors under the company's 2023 Employment Inducement Incentive Award Plan, in compliance with NYSE Rule 303A.08.
Barclays maintains Teladoc Health at Equal-Weight, raises price target to $9 from $7
Barclays has reiterated its "Equal-Weight" rating for Teladoc Health (TDOC) and increased its price target from $7 to $9, representing a 28.6% hike. This new price target suggests a slight upside of 1.2% from the stock's closing price of $8.89 on November 3. Other analysts have recently issued price targets for Teladoc Health ranging from $6.50 to $10.
Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08
Teladoc Health, Inc. has announced the issuance of inducement awards to three new employees, effective November 1, 2026. These awards, consisting of restricted stock units covering 40,768 shares of common stock, were granted in connection with the acquisition of Teledigm Health, LLC and will vest over three years based on continued service. The awards were approved by the Compensation Committee and granted under NYSE Rule 303A.08.
Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08
Teladoc Health, Inc. (NYSE: TDOC) announced that it issued inducement awards to three new employees on November 1, 2026, following the acquisition of Teledigm Health, LLC. These awards consist of restricted stock units covering 40,768 shares of Teladoc Health's common stock, vesting over three years based on continued service. The grants were made under the company's 2023 Employment Inducement Incentive Award Plan, in accordance with NYSE Rule 303A.08.
UBS maintains Teladoc Health at Neutral, raises price target to $9 from $6.50
UBS has maintained its "Neutral" rating on Teladoc Health and increased its price target to $9 from $6.50, representing a 38.5% rise. This new target suggests a 4.3% upside from Teladoc's closing price of $8.63 on November 2nd. Recent analyst actions show price targets for Teladoc Health ranging from $6.50 to $10.
Argus Research Downgrades Teladoc Health(TDOC.US) to Sell Rating
Argus Research has downgraded Teladoc Health (TDOC.US) to a "Sell" rating. This indicates a negative outlook from the research firm regarding the company's stock performance.
Oppenheimer maintains Teladoc Health at Outperform, raises price target to $10 from $7
Oppenheimer has reaffirmed its "Outperform" rating for Teladoc Health (TDOC) and increased its price target from $7 to $10, representing a 42.9% hike. This new price target suggests a 17.5% upside from the stock's closing price of $8.51 on October 30. Other analysts have also recently issued price targets for Teladoc Health, ranging from $6.50 to $10.
Teladoc Health, Inc. (NYSE:TDOC) Released Earnings Last Week And Analysts Lifted Their Price Target To US$8.15
Teladoc Health recently reported strong quarterly results, with revenues exceeding analyst forecasts and statutory losses being smaller than expected. Following these results, analysts moderately uplifted their sentiment, improving loss per share forecasts for 2027 and raising the average price target to US$8.15. Despite a projected revenue decline in 2027 and underperformance compared to the industry, analysts view the reduction in losses positively for the stock's valuation.
Teladoc Health Inc (TDOC) Earnings, Actual EPS, EPS Estimates & Results
Teladoc Health Inc. (TDOC) reported its Q3 2026 earnings, surprising analysts with a reported EPS of -$0.15 against an estimated -$0.22, a 30.96% beat. The company also exceeded revenue estimates, reporting $605.1M compared to the estimated $588.14M. Looking ahead, Teladoc Health expects full-year 2026 revenue of $2.4B, adjusted EBITDA of $277M, and a net loss per share of -$0.95.
Teladoc Health, Inc. Stock 12‑Month Price Target Raised to $7.83, Implies 14% Upside
The average 12-month price target for Teladoc Health, Inc. (TDOC) stock has been increased by analysts from $7.39 to $7.83, with individual forecasts ranging from $6 to $11.5 per share. This updated target suggests a potential upside of approximately 14% from its Oct. 28 closing price. The consensus rating among 23 covering analysts remains "Hold," with 5 Buy recommendations and 18 Holds.
Teladoc Health, Inc. Stock 12‑Month Price Target Raised to $7.83, Implies 14% Upside
Analyst estimates for Teladoc Health, Inc. (TDOC) stock have resulted in an average 12-month price target increase from $7.39 to $7.83, with individual forecasts ranging from $6 to $11.5 per share. This updated target suggests a potential 14% upside based on the October 28 closing price. The consensus rating from 23 analysts remains a "Hold," with 5 Buy, 18 Hold, and 0 Sell recommendations.
Earnings call transcript: Teladoc tops Q3 2026 estimates and lifts outlook
Teladoc Health exceeded third-quarter 2026 estimates, reporting a smaller loss per share and higher revenue than anticipated, driven by strong growth in BetterHelp's insurance business and improved adjusted EBITDA margins. The company also raised its full-year guidance and emphasized its strategic focus on Teladoc One and expanding hybrid care models. Despite ongoing pressures in BetterHelp's cash-pay segment, Teladoc aims for continued progress in 2027 by pivoting towards an in-network insurance model.
Teladoc Health, Inc. (TDOC)
This article provides key financial metrics and investor portfolio information for Teladoc Health, Inc. (TDOC). It details the stock's current price, market capitalization, revenue, and recent performance. The article also highlights significant holdings by prominent investment firms like Renaissance Technologies, Citadel Advisors, and Bridgewater Associates.
Teladoc Health Reports Third Quarter 2026 Results
Teladoc Health (NYSE: TDOC) reported its Third Quarter 2026 financial results, with revenue of $605.1 million, a 3% decrease year-over-year, and a net loss of $26.9 million. Despite the revenue decline, the company saw a 14% increase in adjusted EBITDA to $79.4 million, driven by strong performance in its Integrated Care segment. The BetterHelp segment experienced a revenue decrease due to a focus on insurance-covered services and a decline in direct out-of-pocket users, though insurance revenue exceeded expectations.
Unveiling Teladoc (TDOC) Q3 Outlook: Wall Street Estimates for Key Metrics
Teladoc (TDOC) is projected to report a Q3 quarterly loss of -$0.23 per share and revenues of $585.55 million, indicating year-over-year declines. Analysts also provided estimates for key metrics, including "Revenues by Segment- Integrated Care" at $394.98 million and "Revenues by Segment- BetterHelp" at $192.32 million. The company's U.S. Integrated Care Members are expected to be 99.76 million, and both BetterHelp and Integrated Care Adjusted EBITDA are anticipated to decrease compared to the prior year.
Teladoc Health, Inc. Common Stock (NY: TDOC
This page provides a compilation of recent news headlines and articles concerning Teladoc Health, Inc. (NYSE: TDOC). The headlines span from late 2024 to early 2025, covering topics such as stock performance, analyst ratings, insider interest, partnerships with companies like Amazon, and quarterly earnings reports. It offers insights into market sentiment and expert opinions on Teladoc's future.
Teladoc Health, Inc. Estimates – NYSE:TDOC
This article provides an overview of Teladoc Health, Inc. (NYSE: TDOC) financial estimates available on TradingView. It directs users to explore reported financial data and analyst estimates across various financial statements and valuation metrics. The platform allows comparison of actual results with average, high, and low estimates, and visualization of trends.
Barclays Maintains Teladoc Health(TDOC.US) With Hold Rating, Maintains Target Price $7
Barclays has reiterated its Hold rating for Teladoc Health (TDOC.US) and maintained its target price at $7. This indicates that the firm sees the stock performing in line with the market, with limited upside or downside from its current valuation.
N.L. spent $32.1 million in 2.5 years on private virtual health-care services
Newfoundland and Labrador has spent $32.1 million on private virtual health-care services from Teladoc over two and a half years to address doctor shortages, a measure that some residents find inadequate. While virtual care helps maintain access to urgent services, particularly in rural areas, the provincial medical association emphasizes that it is not a permanent solution and should not replace in-person physician care. The mayor of St. Lawrence highlighted the struggles of older residents with virtual services and the impact of losing local emergency room access, emphasizing the need for more in-person doctors.
Teladoc Health schedules October 28 results for Teladoc Health stock
Teladoc Health (TDOC) is scheduled to release its third-quarter 2026 results on October 28 after market close, with a conference call set for 5:00 p.m. ET. The company's stock was trading at EUR 5.13 on October 20, 2026, and its Q2 revenue was USD 606.93 million, down 4% year-over-year. Investors will be looking for explanations from management regarding enterprise product performance amidst a decline in consumer business revenue.
Teladoc (TDOC) Outperforms Broader Market: What You Need to Know
Teladoc (TDOC) shares closed up 1.06% in the latest trading session, outperforming the S&P 500's daily gain. Despite a recent monthly loss of 10%, the company is set to announce earnings on October 28, 2026, with projected EPS of -$0.23 and revenue of $585.55 million. Teladoc currently holds a Zacks Rank of #3 (Hold) within the Medical Services industry.
Teladoc Health scheduled next results. USD 606.93 million tests Teladoc Health stock
Teladoc Health's stock is under scrutiny as the company prepares to release its third-quarter 2026 results on October 28, 2026. This follows a challenging second quarter where revenue fell by 4.00 percent year-over-year to USD 606.93 million, accompanied by operating and net losses. Investors will be watching to see if new product introductions and cost controls can offset these financial declines.
Teladoc Health scheduled next results. USD 606.93 million tests Teladoc Health stock
Teladoc Health is set to release its third-quarter results on October 28, 2026, which will test its ability to offset declining revenue with product adoption and cost control. The company's Q2 revenue fell 4.00% year over year to USD 606.93 million, with operating and net losses. Analysts currently hold a consensus "Hold" rating on the stock, with an average 12-month price target of USD 7.54.
Lobbying Update: $50,000 of TELADOC HEALTH INC. lobbying was just disclosed
TELADOC HEALTH INC. disclosed $50,000 in lobbying expenditures for Q3 2026, focusing on health data privacy and Medicare Diabetes Prevention Program expansion. The article also details recent insider selling activity, with several executives selling shares, and institutional investor movements, showing both increases and decreases in TDOC holdings. Analyst price targets for TDOC stock range from $7.0 to $10.5.
Lobbying Update: $50,000 of TELADOC HEALTH INC. lobbying was just disclosed
Teladoc Health Inc. recently disclosed $50,000 in lobbying expenditures for Q3 2026, focusing on health data privacy and Medicare Diabetes Prevention Program expansion. Insider trading data shows significant sales by executives, while institutional investors have mixed views, with some adding and others reducing their stakes. Analysts have set a median price target of $8.75 for TDOC.
Teladoc Health schedules October 28 results and Teladoc Health stock trades at EUR 5.18
Teladoc Health has scheduled its third-quarter 2026 results release for October 28, 2026, after reporting a 4.00% revenue decline in the second quarter to USD 606.90 million. The company recently announced a new Chief Legal Officer and introduced new SoloVitals and SoloScribe products. The upcoming earnings call will assess if these new initiatives can bolster enterprise growth amidst ongoing revenue pressure and divided analyst opinions.
DIMENSIONAL FUND ADVISORS LP Adds Teladoc Health Inc (TDOC) Shares -- Stock Looks 26% Undervalued on GF Value
DIMENSIONAL FUND ADVISORS LP recently increased its stake in Teladoc Health Inc (TDOC) by 23.45%, purchasing 1,728,348 shares. Despite this addition, which makes TDOC 5.00% of the company's outstanding shares, the investment represents only 0.01% of Dimensional Fund Advisors' total portfolio. GuruFocus considers TDOC "Modestly Undervalued" with a GF Value of $7.90, yet its quality metrics, including financial strength and profitability, are noted as poor, posing a tension for value investors.
Teladoc Health to Announce Third Quarter 2026 Financial Results
Teladoc Health Inc. (NYSE: TDOC) announced it will release its third quarter 2026 financial results on Wednesday, October 28, 2026, after the market closes. The company will also host a conference call at 5:00 p.m. ET on the same day to discuss the results. Dial-in details and a link to the live audio webcast are provided for interested participants.
Teladoc Health to Announce Third Quarter 2026 Financial Results
Teladoc Health Inc. announced that it will release its third quarter 2026 financial results on Wednesday, October 28, 2026, after market close. The company will host a conference call at 5:00 p.m. ET on the same day to discuss the results. Details for accessing the conference call and live audio webcast are provided.
Teladoc Health to Announce Third Quarter 2026 Financial Results
Teladoc Health announced that it will release its third-quarter 2026 financial results on Wednesday, October 28, 2026, after the market closes. The company will also host a conference call at 5:00 p.m. ET on the same day to discuss the results. Details for accessing the conference call via phone or live audio webcast are provided.
Teladoc Health to Announce Third Quarter 2026 Financial Results
Teladoc Health Inc. (NYSE: TDOC) announced it will release its third-quarter 2026 financial results on Wednesday, October 28, 2026, after the market closes. The company will host a conference call at 5:00 p.m. ET on the same day to discuss these results. Details for accessing the conference call via dialing or live audio webcast are provided.